Pertuzumab/Trastuzumab/Docetaxel Followed by FEC Regimen

Preferred Label : Pertuzumab/Trastuzumab/Docetaxel Followed by FEC Regimen;

NCIt synonyms : Pertuzumab Trastuzumab Docetaxel Followed by FEC; Pertuzumab Trastuzumab Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide; Pertuzumab-Trastuzumab-Docetaxel Followed by Fluorouracil-Epirubicin-Cyclophosphamide; Pertuzumab/Trastuzumab/Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide;

NCIt definition : A regimen consisting of pertuzumab, trastuzumab and docetaxel, followed by fluorouracil, epirubicin and intravenous cyclophosphamide, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.;

NCIt note : Source: NCCN Guidelines 2017;

NCI Metathesaurus CUI : CL524993;

Détails

Origin ID

C138044;

UMLS CUI

C4527350;

Semantic type(s)
- Therapeutic or Preventive Procedure [UMLS semantic type]
chemotherapy_regimen_has_component
- Cyclophosphamide [NCIt concept]
- Docetaxel [NCIt concept]
- Epirubicin Hydrochloride [NCIt concept]
- Fluorouracil [NCIt concept]
- Pertuzumab [NCIt concept]
- Trastuzumab [NCIt concept]
concept_is_in_subset
- Multi-agent Therapeutic Regimens [NCIt concept]
- Pharmacotherapy Regimens [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients